Navigation Links
Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
Date:4/14/2008

nc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody, MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
2. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
3. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
4. Micromet Announces Changes in Management Team
5. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
6. VIRxSYS Presents Data on HIV Vaccine at Keystone HIV Vaccine Symposia
7. NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
8. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
9. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
10. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
11. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 In today,s increasingly global marketplace ... to reflect the needs of a global marketplace ... the needs of key stakeholders while recognizing regional ... According to recent research by benchmarking firm, Best ... companies averaged more than $100,000 in annual spending ...
(Date:12/19/2014)... , December 18, 2014 ... software application/module that is used to store, manipulate, ... RIS comprises a patient tracking and scheduling system, ... integration of RIS with HIS and other databases ... patient registration and patient scheduling, patient list management, ...
(Date:12/19/2014)... Mass. , Dec. 18, 2014  Decision Resources ... the United States will increase to ... will be primarily driven by expansion in the large ... energy devices will be increasingly adopted due to the ... Other key findings from Decision Resources Group,s ...
Breaking Medicine Technology:Building a Best-in-Class Pharma Global Brand Website 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3
... 3, 2011 Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: ... date, it does not expect to commence the manufacture and ... of Caraco,s Fiscal Year 2011, ending March 31, 2011. The ... commence manufacture in the Detroit facility prior to the end ...
... Accuray Incorporated (Nasdaq: ARAY ), a global ... has been named to the NASDAQ Global Select Market, the ... Market is designated for public companies that meet the highest ... liquidity and earnings. "We are honored to ...
Cached Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Provides Update on Remediation Activities 2Caraco Pharmaceutical Laboratories, Ltd. Provides Update on Remediation Activities 3Accuray Elevated to NASDAQ Global Select Market 2Accuray Elevated to NASDAQ Global Select Market 3
(Date:12/19/2014)... It’s very easy to become overwhelmed with ... put to the wayside until Christmas and the New Year ... “itch” and that burning desire to just escape it all ... journey to Telluride with a no-fuss, affordable package. Montrose Days ... the resort, and ensure that all accommodations are met. Plus, ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Sub Zero Ice ... sponsor a blood drive Sunday the 28th from 2pm-6pm at ... & Sawyer Road in Sarasota, FL. , Inquiries regarding time ... you for participating in the donating process, Sub Zero Ice ... flash frozen, custom ice cream. , About Sub Zero Ice ...
(Date:12/19/2014)... The Plantrician Project , ... events, tools and resources for healthcare professionals and ... the world’s leading online cooking school, have joined ... needs: Culinary Rx. As an online food and ... scheduled for debut spring 2015, will be designed ...
(Date:12/19/2014)... Rosa, CA (PRWEB) December 19, 2014 ... and 5x5 SuperClone Rooms. SuperCloset continues to offer indoor ... solutions. Pair one of the new SuperClone Rooms with ... professional, perpetual, and turnkey indoor hydroponic grow room setup. ... in the world, SuperCloset’s SuperPonic SuperCloner 50 . ...
(Date:12/19/2014)... These vanadium reserves are mostly found in China, ... of vanadium were produced globally in 2013, up 11% ... 6.7% AAGR during the period from 2001 to 2013, ... largest consumer, accounted for more than 90% of total ... the chemical industry. , View Full Report at ...
Breaking Medicine News(10 mins):Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 3
... from NewYork-Presbyterian Hospital/Weill Cornell Medical Center will present ... Association,s Annual Meeting in San Francisco, May 29 ... a urologist and professor of urology at NewYork-Presbyterian ... senior author and professor emeritus of urology at ...
... A minimally invasive technique used to destroy kidney tumors ... as surgical removal of tumors in curbing cancer recurrence ... In an article available online in the journal ... radiology at UT Southwestern Medical Center, reported the outcomes ...
... (BRONX, NY) The National Institutes of Health ... Medicine of Yeshiva University a five-year, $3.9 million grant ... in rural South Africa. The findings could alter public ... developing world. "Most cases of XDR-TB are thought ...
... ... demanding enterprise customers with VMware and Microsoft Hyper-V environments. , ... (PRWEB) June 2, 2010 -- VKernel, the ... announced today the general availability of VKernel Optimization Pack 1.4. The latest version ...
... aggressive ones, found in heaviest men, study says , WEDNESDAY, ... patients appears to be linked to patient weight, with heavier ... The finding stems from work involving more than 3,300 prostate ... surgery between 2001 and 2007 to remove a malignant prostate ...
... Risk aversion isn,t inevitable part of aging, researchers find ... says older people make less risky -- and less ... otherwise. , In some cases, older people make just ... people, researchers report. , "It,s not age, per se, ...
Cached Medicine News:Health News:NewYork-Presbyterian/Weill Cornell physician-scientists present at 2010 American Urological Meeting 2Health News:NewYork-Presbyterian/Weill Cornell physician-scientists present at 2010 American Urological Meeting 3Health News:Ablation proved as effective as traditional surgery in treating kidney cancer 2Health News:Einstein awarded NIH grant to study drug-resistant TB 2Health News:Einstein awarded NIH grant to study drug-resistant TB 3Health News:VKernel Raises Scalability and Reporting Bar with Optimization Pack 1.4 2Health News:Size of Prostate Tumor Linked to Patients' Weight 2Health News:Grandpa's Decision-Making Skills May Be Just Fine 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: